Arctoris is a technology-enabled drug discovery services company that leverages automation, robotics, and artificial intelligence to accelerate and improve the drug discovery process. Its flagship product, the Ulysses platform, offers fully automated, high-throughput experimentation combined with advanced data analytics to generate high-quality, reproducible data for drug discovery projects. Arctoris primarily serves biotech and pharmaceutical companies, as well as academic institutions, by providing end-to-end drug discovery services from target validation through preclinical studies. The company addresses the critical problem of slow, costly, and often irreproducible drug discovery workflows, enabling faster timelines and better data quality to ultimately bring new medicines to patients more efficiently[1][2][3][4].
Founded in 2016 in Oxford, UK, Arctoris was established by a team of biotech veterans and engineers with deep expertise in biology, chemistry, and automation. The idea emerged from the recognition that traditional drug discovery methods were outdated, manual, and inefficient, limiting the pace of therapeutic innovation. By integrating robotics with computational approaches and data science, Arctoris developed the world’s first fully automated drug discovery platform, Ulysses. Early traction came from partnerships with pharmaceutical and biotech companies that trusted Arctoris to deliver faster, more reliable experimental data, validating the platform’s potential to transform drug R&D[1][2][3].
Arctoris rides the wave of digital transformation in drug discovery, a field historically hindered by slow, manual processes and poor reproducibility. The convergence of robotics, AI, and big data analytics is reshaping pharmaceutical R&D, making it more efficient and data-driven. The timing is critical as the pharmaceutical industry faces increasing pressure to reduce costs and accelerate timelines for developing new therapies, especially for complex diseases. Arctoris influences the ecosystem by setting new standards for automation and data quality, enabling biotech and pharma companies to innovate faster and with greater confidence in their experimental results[2][4].
Looking ahead, Arctoris is poised to expand its platform capabilities and deepen partnerships with pharmaceutical companies to tackle more complex therapeutic areas such as oncology and neurology. Trends like AI-driven drug discovery, personalized medicine, and integrated data platforms will shape its evolution. As automation and AI become standard in drug R&D, Arctoris’s influence is likely to grow, potentially becoming a cornerstone technology provider that accelerates the development of novel medicines worldwide. Its continued innovation in automation and data science will be key to maintaining a competitive edge and driving the future of drug discovery[2][4].
Arctoris has raised $8.0M in total across 1 funding round.
Arctoris's investors include Amadeus Capital Partners, Molten Ventures.
Arctoris has raised $8.0M across 1 funding round. Most recently, it raised $8.0M Seed in June 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2019 | $8.0M Seed | Amadeus Capital Partners, Molten Ventures |